levonordefrin; procaine hydrochloride; propoxycaine hydrochloride
Drug data last refreshed 17h ago · AI intelligence enriched 2mo ago
RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN is a fixed-dose combination injectable local anesthetic containing procaine hydrochloride, propoxycaine hydrochloride, and levonordefrin (a vasoconstrictor). This classic formulation is used for infiltration and regional anesthesia in dental and minor surgical procedures. The combination enhances anesthetic potency and duration while reducing systemic absorption through vasoconstriction.
This heritage anesthetic faces LOE pressure with moderate competitive intensity (30/100); team focus is likely on retention and cost management rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on this product offers stability in a mature, established market but limited growth trajectory or innovation exposure. Roles emphasize operational efficiency, customer relationship management, and defending market share against generic and branded competitors.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.